Hypertension – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hypertension – Pipeline Review, H1 2017’, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypertension

The report reviews pipeline therapeutics for Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypertension therapeutics and enlists all their major and minor projects

The report assesses Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypertension

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypertension

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

Actelion Ltd

Alnylam Pharmaceuticals Inc

Anacor Pharmaceuticals Inc

AnGes MG Inc

Arena Pharmaceuticals Inc

Ascendis Pharma A/S

Asklepion Pharmaceuticals LLC

AVEO Pharmaceuticals Inc

Bayer AG

Bial – Portela & Ca SA

Biolab Farmaceutica Ltda

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Company

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Conatus Pharmaceuticals Inc

Corion Biotech Srl

Cumberland Pharmaceuticals Inc

Cytokinetics Inc

Daewoong Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

DiaMedica Therapeutics Inc

Eli Lilly and Company

Esperion Therapeutics Inc

F. Hoffmann-La Roche Ltd

Ferring International Center SA

Galectin Therapeutics Inc

Gemphire Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

H. Lundbeck A/S

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

HitGen LTD

Innopharmax Inc

Insmed Inc

Insys Therapeutics Inc

Ionis Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

JW Pharmaceutical Corp

Kowa Company Ltd

Leading BioSciences Inc

Lee's Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

LinXis BV

Liquidia Technologies Inc

Lotus Pharmaceutical Co Ltd

MannKind Corp

Marina Biotech Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

Nanoform Cardiovascular Therapeutics Ltd

Neurim Pharmaceuticals Ltd

Nippon Kayaku Co Ltd

Nippon Shinyaku Co Ltd

Northern Therapeutics Inc

Novartis AG

Noxamet Ltd

Omeros Corp

Peloton Therapeutics Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Pluristem Therapeutics Inc

Polyphor Ltd

Pulmokine Inc

Quantum Genomics SA

Reata Pharmaceuticals Inc

RedHill Biopharma Ltd

Relypsa Inc

Renova Therapeutics Inc

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

rEVO Biologics Inc

Rottapharm Biotech Srl

Sanofi

Savara Inc

Serodus ASA

Shanghai Pharmaceutical Co Ltd

Silence Therapeutics Plc

Simcere Pharmaceutical Group

SteadyMed Therapeutics Inc

Suda Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Company Ltd

The Medicines Company

Theravance Biopharma Inc

Toray Industries Inc

Torrent Pharmaceuticals Ltd

TSH Biopharm Corporation Ltd

United Therapeutics Corp

Vascular BioSciences

Vectura Group Plc

VG Life Sciences Inc

Vicore Pharma AB

Vivus Inc

XORTX Pharma Corp

XuanZhu Pharma Co Ltd

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Hypertension - Overview 8

Hypertension - Therapeutics Development 9

Hypertension - Therapeutics Assessment 36

Hypertension - Companies Involved in Therapeutics Development 54

Hypertension - Drug Profiles 111

Hypertension - Dormant Projects 497

Hypertension - Discontinued Products 511

Hypertension - Product Development Milestones 513

Appendix 522

List of Tables

List of Tables

Number of Products under Development for Hypertension, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hypertension – Pipeline by A1M Pharma AB, H1 2017

Hypertension – Pipeline by Actelion Ltd, H1 2017

Hypertension – Pipeline by Alnylam Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Anacor Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by AnGes MG Inc, H1 2017

Hypertension – Pipeline by Arena Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Ascendis Pharma A/S, H1 2017

Hypertension – Pipeline by Asklepion Pharmaceuticals LLC, H1 2017

Hypertension – Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Bayer AG, H1 2017

Hypertension – Pipeline by Bial – Portela & Ca SA, H1 2017

Hypertension – Pipeline by Biolab Farmaceutica Ltda, H1 2017

Hypertension – Pipeline by BioRestorative Therapies Inc, H1 2017

Hypertension – Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Hypertension – Pipeline by Bristol-Myers Squibb Company, H1 2017

Hypertension – Pipeline by Camurus AB, H1 2017

Hypertension – Pipeline by Capricor Therapeutics Inc, H1 2017

Hypertension – Pipeline by Celsion Corp, H1 2017

Hypertension – Pipeline by Celtaxsys Inc, H1 2017

Hypertension – Pipeline by Chiesi Farmaceutici SpA, H1 2017

Hypertension – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Hypertension – Pipeline by CJ HealthCare Corp, H1 2017

Hypertension – Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Corion Biotech Srl, H1 2017

Hypertension – Pipeline by Cumberland Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Cytokinetics Inc, H1 2017

Hypertension – Pipeline by Daewoong Co Ltd, H1 2017

Hypertension – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Hypertension – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Hypertension – Pipeline by DiaMedica Therapeutics Inc, H1 2017

Hypertension – Pipeline by Eli Lilly and Company, H1 2017

Hypertension – Pipeline by Esperion Therapeutics Inc, H1 2017

Hypertension – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hypertension – Pipeline by Ferring International Center SA, H1 2017

Hypertension – Pipeline by Galectin Therapeutics Inc, H1 2017

Hypertension – Pipeline by Gemphire Therapeutics Inc, H1 2017

Hypertension – Pipeline by Gilead Sciences Inc, H1 2017

Hypertension – Pipeline by GlaxoSmithKline Plc, H1 2017

Hypertension – Pipeline by H. Lundbeck A/S, H1 2017

Hypertension – Pipeline by HanAll Biopharma Co Ltd, H1 2017

Hypertension – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Hypertension – Pipeline by HitGen LTD, H1 2017

Hypertension – Pipeline by Innopharmax Inc, H1 2017

Hypertension – Pipeline by Insmed Inc, H1 2017

Hypertension – Pipeline by Insys Therapeutics Inc, H1 2017

Hypertension – Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Hypertension – Pipeline by Johnson & Johnson, H1 2017

Hypertension – Pipeline by JW Pharmaceutical Corp, H1 2017

Hypertension – Pipeline by Kowa Company Ltd, H1 2017

Hypertension – Pipeline by Leading BioSciences Inc, H1 2017

Hypertension – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Hypertension – Pipeline by Les Laboratoires Servier SAS, H1 2017

Hypertension – Pipeline by LinXis BV, H1 2017

Hypertension – Pipeline by Liquidia Technologies Inc, H1 2017

Hypertension – Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Hypertension – Pipeline by MannKind Corp, H1 2017

Hypertension – Pipeline by Marina Biotech Inc, H1 2017

Hypertension – Pipeline by Merck & Co Inc, H1 2017

Hypertension – Pipeline by Mezzion Pharma Co Ltd, H1 2017

Hypertension – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Hypertension – Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H1 2017

Hypertension – Pipeline by Neurim Pharmaceuticals Ltd, H1 2017

Hypertension – Pipeline by Nippon Kayaku Co Ltd, H1 2017

Hypertension – Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Hypertension – Pipeline by Northern Therapeutics Inc, H1 2017

Hypertension – Pipeline by Novartis AG, H1 2017

Hypertension – Pipeline by Noxamet Ltd, H1 2017

Hypertension – Pipeline by Omeros Corp, H1 2017

Hypertension – Pipeline by Peloton Therapeutics Inc, H1 2017

Hypertension – Pipeline by Pfizer Inc, H1 2017

Hypertension – Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by Pluristem Therapeutics Inc, H1 2017

Hypertension – Pipeline by Polyphor Ltd, H1 2017

Hypertension – Pipeline by Pulmokine Inc, H1 2017

Hypertension – Pipeline by Quantum Genomics SA, H1 2017

Hypertension – Pipeline by Reata Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by RedHill Biopharma Ltd, H1 2017

Hypertension – Pipeline by Relypsa Inc, H1 2017

Hypertension – Pipeline by Renova Therapeutics Inc, H1 2017

Hypertension – Pipeline by Respira Therapeutics Inc, H1 2017

Hypertension – Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Hypertension – Pipeline by rEVO Biologics Inc, H1 2017

Hypertension – Pipeline by Rottapharm Biotech Srl, H1 2017

Hypertension – Pipeline by Sanofi, H1 2017

Hypertension – Pipeline by Savara Inc, H1 2017

Hypertension – Pipeline by Serodus ASA, H1 2017

Hypertension – Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017

Hypertension – Pipeline by Silence Therapeutics Plc, H1 2017

Hypertension – Pipeline by Simcere Pharmaceutical Group, H1 2017

Hypertension – Pipeline by SteadyMed Therapeutics Inc, H1 2017

Hypertension – Pipeline by Suda Ltd, H1 2017

Hypertension – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Hypertension – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Hypertension – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Hypertension – Pipeline by The Medicines Company, H1 2017

Hypertension – Pipeline by Theravance Biopharma Inc, H1 2017

Hypertension – Pipeline by Toray Industries Inc, H1 2017

Hypertension – Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Hypertension – Pipeline by TSH Biopharm Corporation Ltd, H1 2017

Hypertension – Pipeline by United Therapeutics Corp, H1 2017

Hypertension – Pipeline by Vascular BioSciences, H1 2017

Hypertension – Pipeline by Vectura Group Plc, H1 2017

Hypertension – Pipeline by VG Life Sciences Inc, H1 2017

Hypertension – Pipeline by Vicore Pharma AB, H1 2017

Hypertension – Pipeline by Vivus Inc, H1 2017

Hypertension – Pipeline by XORTX Pharma Corp, H1 2017

Hypertension – Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Hypertension – Pipeline by Yuhan Corp, H1 2017

Hypertension – Dormant Projects, H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..1), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..2), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..3), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..4), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..5), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..6), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..7), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..8), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..9), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..10), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..11), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..12), H1 2017

Hypertension – Dormant Projects, H1 2017 (Contd..13), H1 2017

Hypertension – Discontinued Products, H1 2017

Hypertension – Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Hypertension, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports